News
09-11-2010, 04:16 AM
AstraZeneca (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved the 500mg dose of FASLODEX® (fulvestrant) Injection, replacing the previously approved monthly dose of 250mg, for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy...
More... (http://mnt.to/f/3JCz)
More... (http://mnt.to/f/3JCz)